---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-151011"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:03:08.937938+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Magenta Q1 net loss $23M; MGTA-117 shows target binding and rapid clearance at lowest dose

## Summary
- Net loss of $23.0M for Q1 2022 vs. $17.5M in Q1 2021; R&D expenses rose to $16.5M from $11.7M.
- Cash, equivalents and marketable securities $156.6M as of Mar 31, 2022; expected to fund operations into Q2 2024.
- Phase 1/2 MGTA-117 Cohort 1 data: target binding on CD117+ cells, rapid drug clearance within 48 hours, no serious drug-related AEs; dose escalation to Cohort 2 (0.04 mg/kg) underway.
- One patient with low blast burden showed ~83% reduction of bone marrow blasts at day 14; supports planned transition to transplant-eligible AML patients.
- IND-enabling studies for CD45-ADC ongoing; key toxicology results expected 2H 2022. MGTA-145 sickle cell trial startup progressing; initial data expected 2H 2022.

## SEC filing metadata
- accession: 0001193125-22-151011
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312522151011/0001193125-22-151011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312522151011/d264834d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-151011
- JSON: https://secwatch.observer/filing/0001193125-22-151011.json
- Plain text: https://secwatch.observer/filing/0001193125-22-151011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.